Diagnostics to help reduce the burden of disease

Nonagen Bioscience® combines urine-based liquid biopsy, multiplex protein biomarkers, clinical data and proprietary computational algorithms to detect cancer, monitor recurrence and predict treatment response.

3 Commercial Tests | 5,500+ Patients | 40+ Publications | $21M+ NIH/NCI Funding

Clearly different. Clearly better.